Bernd Möller - Concepedia

Concepedia

Author

Bernd Möller

Goethe University Frankfurt

Also Known As

Bernd Moller, Bernd Möller

18

Publications

1.2K

Citations

12

H-Index

18

Concepts

All Affiliations

Goethe University Frankfurt Charité - Universitätsmedizin Berlin Heidelberg University University Hospital Leipzig Medizinische Hochschule Hannover

BM

About

Bernd Möller is an author at Goethe University Frankfurt specializing in medicine, hepatology, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	3	3	285
2	Hepatology	2	2	243
3	Immunology	2	2	185
4	Health Sciences	1	1	100
5	Microbiology	1	1	100

Bernd Möller

×

12

Publications

1.2K

Citations

12

H-Index

	Year	Citations
Long-Term Efficacy of Tenofovir Monotherapy for Hepatitis B Virus-Monoinfected Patients After Failure of Nucleoside/Nucleotide Analogues Florian van Bömmel, Robert A. de Man, Heiner Wedemeyer, Hepatology	2009	330
Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy Florian van Bömmel, Bernhard Zöllner, Christoph Sarrazin, Hepatology	2006	289
Tenofovir Is Effective Alone or With Emtricitabine in Adefovir-Treated Patients With Chronic-Hepatitis B Virus Infection Thomas Berg, Patrick Marcellin, Fabien Zoulim, Gastroenterology HepatologyAdefovir-treated PatientsViral HepatitisImmunologyHepatitis B	2010	143
Ursodeoxycholic acid-induced changes of plasma and urinary bile acids in patients with primary biliary cirrhosis Adolf Stiehl, Gerda Rudolph, R. Raedsch, Hepatology	1990	119
ARE ANTIMITOCHONDRIAL ANTIBODIES IN PRIMARY BILIARY CIRRHOSIS INDUCED BY R(ROUGH)-MUTANTS OF ENTEROBACTERIACEAE? R. Stemerowicz, Bernd Möller, Arne Rodloff, The Lancet HepatologyHealth SciencesBiliary TractLiver PhysiologyPathogenesis	1988	100
Individualized treatment strategy according to early viral kinetics in hepatitis C virus type 1–infected patients†‡ Thomas Berg, V Weich, G Teuber, Hepatology	2009	55
Improved Responses to Pegylated Interferon Alfa-2b and Ribavirin by Individualizing Treatment for 24–72 Weeks Christoph Sarrazin, Susanne Schwendy, Bernd Möller, Gastroenterology PharmacologyImmunologyPegylated Interferon Alfa-2bIndividualizing TreatmentAntiviral Therapy	2011	42
Sex-specific effects of TLR9 promoter variants on spontaneous clearance of HCV infection Janett Fischer, Alexander N.R. Weber, Stephan Böhm, Gut	2016	38
Evolution of Adefovir-Resistant HBV Polymerase Gene Variants after Switching to Tenofovir Disoproxil Fumarate Monotherapy Florian van Bömmel, Jörg Trojan, Katja Deterding, Antiviral Therapy	2012	17
Treatment of Naïve Patients with Chronic Hepatitis C Genotypes 2 and 3 with Pegylated Interferon Alpha and Ribavirin in a Real World Setting: Relevance for the New Era of DAA Benjamin Heidrich, Steffen B. Wiegand, Peter Buggisch, PLoS ONE	2014	15

Page 1